Abstract: Research on peptide receptor radionuclide therapy (PRRT) for advanced gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is gradually advancing locally and abroad. The basic principle of PRRT for treating GEP-NEN is that radioactive nuclide-labeled somatostatin analogues can combine with somatostatin receptors (SSTRs) overexpressed on the neuroendocrine tumor cell surface so that the radioactive drug can be incorporated into the tumor cells. For inoperable or metastatic GEP-NEN, PRRT has shown better efficacy than traditional somatostatin analogue therapy, targeted therapy, and systematic chemotherapy in some clinical studies and it can prolong survival time. In particular, ¹⁷⁷Lu-dotatate has been approved as a PRRT drug by European and American authorities. In terms of safety, as a radionuclide therapy, PRRT can cause adverse reactions such as bone marrow toxicity and nephrotoxicity. However, some studies have shown that it can be safely applied within a specific dose range.